glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus Comparison of GLP-1 receptor agonists

2 Experts recommend that patient-specific considerations and shared decision-making should be incorporated into treatment decisions

Human-focused reviews and meta-analyses have debated the magnitude and clinical relevance of lean mass changes during GLP-1RA therapy [41], whereas preclinical studies report context-dependent protection against muscle wasting [42, 43]

Zepbound ( Tirzepatide ): Zepbound is a newer medication that works through two pathways to help with both weight loss and blood sugar control

Starting around age 35, women start to lose muscle mass each year, and that rate speeds up over time, unless you do things like lifting weights or practicing yoga to maintain or build on what you have

View at Publisher | View at Google Scholar Wang Y et al

doi: 10.1056/NEJMoa1612917 16 GreenJBHernandezAFDAgostinoRBGrangerCBJanmohamedSJonesNPet al